F-star Therapeutics GAAP EPS of -$0.88

  • F-star Therapeutics press release (NASDAQ:FSTX): Q2 GAAP EPS of -$0.88.
  • Cash and cash equivalents were $53.0 million as of June 30, 2022, compared to $78.5 million at December 31, 2021.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.